Resmed (RMD) announced its home sleep apnea test, NightOwl, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test designed to offer healthcare providers a simplified, accurate, and efficient way to diagnose obstructive sleep apnea from the comfort of an individual’s home. NightOwl is a disposable HSAT device that records up to 10 nights of sleep data for a single patient, capturing night-to-night variability and providing clinicians with a comprehensive view of an individual’s sleep patterns. Sleep data is sent remotely to a cloud-based diagnostic platform for physician analysis and review, enabling quick interpretation, streamlining diagnostic workflows, and helping individuals receive more timely diagnoses, if applicable.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed price target lowered to $280 from $290 at BofA
- Resmed’s Resilience and Growth Prospects Amid Tariff Challenges: A Buy Recommendation
- Morgan Stanley Sees Near-Term Rally Ahead — Here Are 2 Stocks to Bet on It
- ResMed initiated with an Overweight at Morgan Stanley
- ResMed announces publication of data on CPAP therapy